Table 5 Description of MACE depending on prior antithrombotic therapy
From: Evaluation of therapy management and outcome in Takotsubo syndrome
Study population n = 72 | ||||||
|---|---|---|---|---|---|---|
MACE | No AT n = 3 | AT n = 28 | Dual AT n = 29 | OAC n = 6 | AT + OAC n = 4 | Triple therapy n = 2 |
No event | 2 (3%) | 25 (35%) | 25 (35%) | 5 (7%) | 4 (6%) | 2 (3%) |
With Event | 1 (1%) | 3 (4%) | 4 (6%) | 1 (1%) | 0 | 0 |
Myocardial infarction | 0 | 1 (1%) | 0 | 0 | 0 | 0 |
Stroke | 0 | 1 (1%) | 1 (1%) | 1 (1%) | 0 | 0 |
Recurrence of TTS | 0 | 0 | 1 (1%) | 0 | 0 | 0 |
Death | 1 (1%) | 1 (1%) | 2 (3%) | 0 | 0 | 0 |